Clinical Trials Logo

Follicular Lymphomas clinical trials

View clinical trials related to Follicular Lymphomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT02650999 Completed - Clinical trials for Follicular Lymphomas

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Start date: January 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas relapsed/refractory after CTL019. 12 total patients will be enrolled. Safety of pembrolizumab (primary endpoint) will be determined using a Bayesian monitoring rule for treatment-related adverse events causing drug discontinuation. Secondary efficacy endpoints include overall response rate and progression-free survival.

NCT ID: NCT01474681 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Start date: January 9, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.

NCT ID: NCT00991211 Completed - Clinical trials for Follicular Lymphomas

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Start date: January 2004
Phase: Phase 3
Study type: Interventional

The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival (PFS).

NCT ID: NCT00877214 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

MAINTAIN
Start date: April 1, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.